Gene symbol | CXCL5 | Synonyms | ENA-78, SCYB5 | Type of gene | protein-coding |
Chromosome | 4 | Map location | 4q13.3 | dbXrefs | |
Gene perturbation-related omics dataset | PerturbAtlas | ||||
Description | C-X-C motif chemokine ligand 5 |
Gene symbol | S | Synonyms | E2 | Type of gene | protein-coding |
Chromosome | - | Map location | NC_004718.3 (21492..25259) | dbXrefs | |
Gene perturbation-related omics dataset | PerturbAtlas | ||||
Description | spike glycoprotein |
GTO ID | GTC3301 |
Trial ID | NCT05677893 |
Disease | Severe Acute Respiratory Syndrome Coronavirus 2 |
Altered gene | S|CXCL5 |
Therapeutic/Target gene | Target gene |
Therapy | siRNA |
Treatment | MBS-COV|SNS812 |
Phase | Phase1 |
Recruitment status | Completed |
Title | A Phase I, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of Inhaled MBS-COV (SNS812) in Healthy Participants |
Year | 2022 |
Country | United States |
Company sponsor | Oneness Biotech Co., Ltd. |
Other ID(s) | SNS812CLCT01 |
Cohort1: MBS-COV | |||||||
|
|||||||
Cohort2: Placebo | |||||||
|